RNA therapy uses antisense oligonucleotides (ASOs) as therapeutic tools. Upon local administration to the target tissue, ASOs have a very long half-life. In this way high and long-term exposure is achieved locally, while the exposure of the drug to the rest of the body is very low. At the same time, the dosing frequency is also low (every 3-4 months).
DCRT Charter
The DCRT charter documents the information pertinent to how DCRT (Dutch Center for RNA Therapeutics) operates and what is aspired. The charter includes the needs, scope, justification, and resource commitment and can be downloaded here.
DCRT Annual Report 2023
DCRT's activities and progress in 2023 towards the design and the development of individualized RNA therapies are detailed in our current annual report. Would you like to learn more about our work? Send us an email and we will get back to you promptly.
DCRT Annual Report 2021-2022
DCRT is proud to present its first annual report which describes the consortium's activities in 2021 and 2022, the scientific progress and our plans for 2023. Any questions after reading our report? Please contact us at dcrt@lumc.nl.
Let us know your questions or suggestions.